Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40009124
Localisation
Switzerland
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
18/09/2025
Statut
Classification
1.5°C
Année cible
2033
Near-Term Targets: POLYPEPTIDE GROUP AG commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2023 base year. POLYPEPTIDE GROUP AG also commits to increase active annual sourcing of renewable electricity from 54.0% in 2023 to 100% by 2029 and to continue active annual sourcing of 100% renewable electricity through 2030. POLYPEPTIDE GROUP AG further commits to reduce scope 3 GHG emissions from purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution and waste generated in operations 61.1% per EUR value added by 2033 from a 2022 base year. Furthermore, POLYPEPTIDE GROUP AG commits that 45% of its suppliers by spend covering purchased goods and services, will have science-based targets by 2029.
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
CH1110760852
LEI
5067007JCKTPOX4G9758
Source : Science Based Targets initiative | Données publiques